Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.
Identifieur interne : 001E40 ( PubMed/Checkpoint ); précédent : 001E39; suivant : 001E41Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.
Auteurs : Karina Yusim [États-Unis] ; William Fischer ; Hyejin Yoon ; James Thurmond ; Paul W. Fenimore ; Georg Lauer ; Bette Korber ; Carla KuikenSource :
- The Journal of general virology [ 1465-2099 ] ; 2010.
Descripteurs français
- KwdFr :
- Déterminants antigéniques des lymphocytes T (génétique), Déterminants antigéniques des lymphocytes T (immunologie), Génotype, Hepacivirus (génétique), Hepacivirus (immunologie), Humains, Hépatite C (), Hépatite C (immunologie), Lymphocytes T (immunologie), Protéines recombinantes (génétique), Protéines recombinantes (immunologie), Protéines virales non structurales (génétique), Protéines virales non structurales (immunologie), Vaccins contre les hépatites virales (immunologie), Vaccins synthétiques (génétique), Vaccins synthétiques (immunologie), Variation génétique.
- MESH :
- génétique : Déterminants antigéniques des lymphocytes T, Hepacivirus, Protéines recombinantes, Protéines virales non structurales, Vaccins synthétiques.
- immunologie : Déterminants antigéniques des lymphocytes T, Hepacivirus, Hépatite C, Lymphocytes T, Protéines recombinantes, Protéines virales non structurales, Vaccins contre les hépatites virales, Vaccins synthétiques.
- Génotype, Humains, Hépatite C, Variation génétique.
English descriptors
- KwdEn :
- Epitopes, T-Lymphocyte (genetics), Epitopes, T-Lymphocyte (immunology), Genetic Variation, Genotype, Hepacivirus (genetics), Hepacivirus (immunology), Hepatitis C (immunology), Hepatitis C (prevention & control), Humans, Recombinant Proteins (genetics), Recombinant Proteins (immunology), T-Lymphocytes (immunology), Vaccines, Synthetic (genetics), Vaccines, Synthetic (immunology), Viral Hepatitis Vaccines (immunology), Viral Nonstructural Proteins (genetics), Viral Nonstructural Proteins (immunology).
- MESH :
- chemical , genetics : Epitopes, T-Lymphocyte, Recombinant Proteins, Vaccines, Synthetic, Viral Nonstructural Proteins.
- chemical , immunology : Epitopes, T-Lymphocyte, Recombinant Proteins, Vaccines, Synthetic, Viral Hepatitis Vaccines, Viral Nonstructural Proteins.
- genetics : Hepacivirus.
- immunology : Hepacivirus, Hepatitis C, T-Lymphocytes.
- prevention & control : Hepatitis C.
- Genetic Variation, Genotype, Humans.
Abstract
Immunological control of hepatitis C virus (HCV) is possible and is probably mediated by host T-cell responses, but the genetic diversity of the virus poses a major challenge to vaccine development. We considered monovalent and polyvalent candidates for an HCV vaccine, including natural, consensus and synthetic 'mosaic' sequence cocktails. Mosaic vaccine reagents were designed using a computational approach first applied to and demonstrated experimentally for human immunodeficiency virus type 1 (HIV-Delta). Mosaic proteins resemble natural proteins, but are assembled from fragments of natural sequences via a genetic algorithm and optimized to maximize the coverage of potential T-cell epitopes (all 9-mers) found in natural sequences and to minimize the inclusion of rare 9-mers to avoid vaccine-specific responses. Genotype 1-specific and global vaccine cocktails were evaluated. Among vaccine candidates considered, polyvalent mosaic sequences provided the best coverage of both known and potential epitopes and had the fewest rare epitopes. A global vaccine based on conserved proteins across genotypes may be feasible, as a five-antigen mosaic cocktail provided 90, 77 and 70% coverage of the Core, NS3 and NS4 proteins, respectively; protein coverage diminished with increased protein variability, dropping to 38% for NS2. For the genotype 1-specific vaccine, the H77 prototype vaccine sequence matched only 50% of the potential epitopes in the population, whilst a polyprotein three-antigen mosaic cocktail increased potential epitope coverage to 83%. More than 75% coverage of all HCV proteins was achieved with a three-antigen mosaic cocktail, suggesting that genotype-specific vaccines could also include the more variable proteins.
DOI: 10.1099/vir.0.017491-0
PubMed: 20053820
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:20053820Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.</title>
<author><name sortKey="Yusim, Karina" sort="Yusim, Karina" uniqKey="Yusim K" first="Karina" last="Yusim">Karina Yusim</name>
<affiliation wicri:level="2"><nlm:affiliation>Los Alamos National Laboratory, Theory Division, Los Alamos, NM 87545, USA. kyusim@lanl.gov</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Los Alamos National Laboratory, Theory Division, Los Alamos, NM 87545</wicri:regionArea>
<placeName><region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fischer, William" sort="Fischer, William" uniqKey="Fischer W" first="William" last="Fischer">William Fischer</name>
</author>
<author><name sortKey="Yoon, Hyejin" sort="Yoon, Hyejin" uniqKey="Yoon H" first="Hyejin" last="Yoon">Hyejin Yoon</name>
</author>
<author><name sortKey="Thurmond, James" sort="Thurmond, James" uniqKey="Thurmond J" first="James" last="Thurmond">James Thurmond</name>
</author>
<author><name sortKey="Fenimore, Paul W" sort="Fenimore, Paul W" uniqKey="Fenimore P" first="Paul W" last="Fenimore">Paul W. Fenimore</name>
</author>
<author><name sortKey="Lauer, Georg" sort="Lauer, Georg" uniqKey="Lauer G" first="Georg" last="Lauer">Georg Lauer</name>
</author>
<author><name sortKey="Korber, Bette" sort="Korber, Bette" uniqKey="Korber B" first="Bette" last="Korber">Bette Korber</name>
</author>
<author><name sortKey="Kuiken, Carla" sort="Kuiken, Carla" uniqKey="Kuiken C" first="Carla" last="Kuiken">Carla Kuiken</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20053820</idno>
<idno type="pmid">20053820</idno>
<idno type="doi">10.1099/vir.0.017491-0</idno>
<idno type="wicri:Area/PubMed/Corpus">001F72</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F72</idno>
<idno type="wicri:Area/PubMed/Curation">001F72</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F72</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001E40</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001E40</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.</title>
<author><name sortKey="Yusim, Karina" sort="Yusim, Karina" uniqKey="Yusim K" first="Karina" last="Yusim">Karina Yusim</name>
<affiliation wicri:level="2"><nlm:affiliation>Los Alamos National Laboratory, Theory Division, Los Alamos, NM 87545, USA. kyusim@lanl.gov</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Los Alamos National Laboratory, Theory Division, Los Alamos, NM 87545</wicri:regionArea>
<placeName><region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fischer, William" sort="Fischer, William" uniqKey="Fischer W" first="William" last="Fischer">William Fischer</name>
</author>
<author><name sortKey="Yoon, Hyejin" sort="Yoon, Hyejin" uniqKey="Yoon H" first="Hyejin" last="Yoon">Hyejin Yoon</name>
</author>
<author><name sortKey="Thurmond, James" sort="Thurmond, James" uniqKey="Thurmond J" first="James" last="Thurmond">James Thurmond</name>
</author>
<author><name sortKey="Fenimore, Paul W" sort="Fenimore, Paul W" uniqKey="Fenimore P" first="Paul W" last="Fenimore">Paul W. Fenimore</name>
</author>
<author><name sortKey="Lauer, Georg" sort="Lauer, Georg" uniqKey="Lauer G" first="Georg" last="Lauer">Georg Lauer</name>
</author>
<author><name sortKey="Korber, Bette" sort="Korber, Bette" uniqKey="Korber B" first="Bette" last="Korber">Bette Korber</name>
</author>
<author><name sortKey="Kuiken, Carla" sort="Kuiken, Carla" uniqKey="Kuiken C" first="Carla" last="Kuiken">Carla Kuiken</name>
</author>
</analytic>
<series><title level="j">The Journal of general virology</title>
<idno type="eISSN">1465-2099</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Epitopes, T-Lymphocyte (genetics)</term>
<term>Epitopes, T-Lymphocyte (immunology)</term>
<term>Genetic Variation</term>
<term>Genotype</term>
<term>Hepacivirus (genetics)</term>
<term>Hepacivirus (immunology)</term>
<term>Hepatitis C (immunology)</term>
<term>Hepatitis C (prevention & control)</term>
<term>Humans</term>
<term>Recombinant Proteins (genetics)</term>
<term>Recombinant Proteins (immunology)</term>
<term>T-Lymphocytes (immunology)</term>
<term>Vaccines, Synthetic (genetics)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Viral Hepatitis Vaccines (immunology)</term>
<term>Viral Nonstructural Proteins (genetics)</term>
<term>Viral Nonstructural Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Déterminants antigéniques des lymphocytes T (génétique)</term>
<term>Déterminants antigéniques des lymphocytes T (immunologie)</term>
<term>Génotype</term>
<term>Hepacivirus (génétique)</term>
<term>Hepacivirus (immunologie)</term>
<term>Humains</term>
<term>Hépatite C ()</term>
<term>Hépatite C (immunologie)</term>
<term>Lymphocytes T (immunologie)</term>
<term>Protéines recombinantes (génétique)</term>
<term>Protéines recombinantes (immunologie)</term>
<term>Protéines virales non structurales (génétique)</term>
<term>Protéines virales non structurales (immunologie)</term>
<term>Vaccins contre les hépatites virales (immunologie)</term>
<term>Vaccins synthétiques (génétique)</term>
<term>Vaccins synthétiques (immunologie)</term>
<term>Variation génétique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Epitopes, T-Lymphocyte</term>
<term>Recombinant Proteins</term>
<term>Vaccines, Synthetic</term>
<term>Viral Nonstructural Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Epitopes, T-Lymphocyte</term>
<term>Recombinant Proteins</term>
<term>Vaccines, Synthetic</term>
<term>Viral Hepatitis Vaccines</term>
<term>Viral Nonstructural Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Déterminants antigéniques des lymphocytes T</term>
<term>Hepacivirus</term>
<term>Protéines recombinantes</term>
<term>Protéines virales non structurales</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Déterminants antigéniques des lymphocytes T</term>
<term>Hepacivirus</term>
<term>Hépatite C</term>
<term>Lymphocytes T</term>
<term>Protéines recombinantes</term>
<term>Protéines virales non structurales</term>
<term>Vaccins contre les hépatites virales</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hepacivirus</term>
<term>Hepatitis C</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hepatitis C</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Genetic Variation</term>
<term>Genotype</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Génotype</term>
<term>Humains</term>
<term>Hépatite C</term>
<term>Variation génétique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Immunological control of hepatitis C virus (HCV) is possible and is probably mediated by host T-cell responses, but the genetic diversity of the virus poses a major challenge to vaccine development. We considered monovalent and polyvalent candidates for an HCV vaccine, including natural, consensus and synthetic 'mosaic' sequence cocktails. Mosaic vaccine reagents were designed using a computational approach first applied to and demonstrated experimentally for human immunodeficiency virus type 1 (HIV-Delta). Mosaic proteins resemble natural proteins, but are assembled from fragments of natural sequences via a genetic algorithm and optimized to maximize the coverage of potential T-cell epitopes (all 9-mers) found in natural sequences and to minimize the inclusion of rare 9-mers to avoid vaccine-specific responses. Genotype 1-specific and global vaccine cocktails were evaluated. Among vaccine candidates considered, polyvalent mosaic sequences provided the best coverage of both known and potential epitopes and had the fewest rare epitopes. A global vaccine based on conserved proteins across genotypes may be feasible, as a five-antigen mosaic cocktail provided 90, 77 and 70% coverage of the Core, NS3 and NS4 proteins, respectively; protein coverage diminished with increased protein variability, dropping to 38% for NS2. For the genotype 1-specific vaccine, the H77 prototype vaccine sequence matched only 50% of the potential epitopes in the population, whilst a polyprotein three-antigen mosaic cocktail increased potential epitope coverage to 83%. More than 75% coverage of all HCV proteins was achieved with a three-antigen mosaic cocktail, suggesting that genotype-specific vaccines could also include the more variable proteins.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20053820</PMID>
<DateCompleted><Year>2010</Year>
<Month>04</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>04</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1465-2099</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>91</Volume>
<Issue>Pt 5</Issue>
<PubDate><Year>2010</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of general virology</Title>
<ISOAbbreviation>J. Gen. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.</ArticleTitle>
<Pagination><MedlinePgn>1194-206</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1099/vir.0.017491-0</ELocationID>
<Abstract><AbstractText>Immunological control of hepatitis C virus (HCV) is possible and is probably mediated by host T-cell responses, but the genetic diversity of the virus poses a major challenge to vaccine development. We considered monovalent and polyvalent candidates for an HCV vaccine, including natural, consensus and synthetic 'mosaic' sequence cocktails. Mosaic vaccine reagents were designed using a computational approach first applied to and demonstrated experimentally for human immunodeficiency virus type 1 (HIV-Delta). Mosaic proteins resemble natural proteins, but are assembled from fragments of natural sequences via a genetic algorithm and optimized to maximize the coverage of potential T-cell epitopes (all 9-mers) found in natural sequences and to minimize the inclusion of rare 9-mers to avoid vaccine-specific responses. Genotype 1-specific and global vaccine cocktails were evaluated. Among vaccine candidates considered, polyvalent mosaic sequences provided the best coverage of both known and potential epitopes and had the fewest rare epitopes. A global vaccine based on conserved proteins across genotypes may be feasible, as a five-antigen mosaic cocktail provided 90, 77 and 70% coverage of the Core, NS3 and NS4 proteins, respectively; protein coverage diminished with increased protein variability, dropping to 38% for NS2. For the genotype 1-specific vaccine, the H77 prototype vaccine sequence matched only 50% of the potential epitopes in the population, whilst a polyprotein three-antigen mosaic cocktail increased potential epitope coverage to 83%. More than 75% coverage of all HCV proteins was achieved with a three-antigen mosaic cocktail, suggesting that genotype-specific vaccines could also include the more variable proteins.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yusim</LastName>
<ForeName>Karina</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Los Alamos National Laboratory, Theory Division, Los Alamos, NM 87545, USA. kyusim@lanl.gov</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fischer</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yoon</LastName>
<ForeName>Hyejin</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Thurmond</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fenimore</LastName>
<ForeName>Paul W</ForeName>
<Initials>PW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lauer</LastName>
<ForeName>Georg</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Korber</LastName>
<ForeName>Bette</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kuiken</LastName>
<ForeName>Carla</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2010</Year>
<Month>01</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Gen Virol</MedlineTA>
<NlmUniqueID>0077340</NlmUniqueID>
<ISSNLinking>0022-1317</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014761">Viral Hepatitis Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014761" MajorTopicYN="N">Viral Hepatitis Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20053820</ArticleId>
<ArticleId IdType="pii">vir.0.017491-0</ArticleId>
<ArticleId IdType="doi">10.1099/vir.0.017491-0</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Nouveau-Mexique</li>
</region>
</list>
<tree><noCountry><name sortKey="Fenimore, Paul W" sort="Fenimore, Paul W" uniqKey="Fenimore P" first="Paul W" last="Fenimore">Paul W. Fenimore</name>
<name sortKey="Fischer, William" sort="Fischer, William" uniqKey="Fischer W" first="William" last="Fischer">William Fischer</name>
<name sortKey="Korber, Bette" sort="Korber, Bette" uniqKey="Korber B" first="Bette" last="Korber">Bette Korber</name>
<name sortKey="Kuiken, Carla" sort="Kuiken, Carla" uniqKey="Kuiken C" first="Carla" last="Kuiken">Carla Kuiken</name>
<name sortKey="Lauer, Georg" sort="Lauer, Georg" uniqKey="Lauer G" first="Georg" last="Lauer">Georg Lauer</name>
<name sortKey="Thurmond, James" sort="Thurmond, James" uniqKey="Thurmond J" first="James" last="Thurmond">James Thurmond</name>
<name sortKey="Yoon, Hyejin" sort="Yoon, Hyejin" uniqKey="Yoon H" first="Hyejin" last="Yoon">Hyejin Yoon</name>
</noCountry>
<country name="États-Unis"><region name="Nouveau-Mexique"><name sortKey="Yusim, Karina" sort="Yusim, Karina" uniqKey="Yusim K" first="Karina" last="Yusim">Karina Yusim</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001E40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:20053820 |texte= Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:20053820" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
This area was generated with Dilib version V0.6.33. |